College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, UK.
Biochem Soc Trans. 2011 Jan;39(1):1-13. doi: 10.1042/BST0390001.
It is essential to life that a balance is maintained between processes that produce ATP and those that consume it. An obvious way to do this would be to have systems that monitor the levels of ATP and ADP, although because of the adenylate kinase reaction (2ADP↔ATP+AMP), AMP is actually a more sensitive indicator of energy stress than ADP. Following the discoveries that glycogen phosphorylase and phosphofructokinase were regulated by AMP and ATP, Daniel Atkinson proposed that all enzymes at branch points between biosynthesis and degradation would be regulated by adenine nucleotides. This turned out to be correct, but what Atkinson did not anticipate was that sensing of nucleotides would, in most cases, be performed not by the metabolic enzymes themselves, but by a signalling protein, AMPK (AMP-activated protein kinase). AMPK occurs in essentially all eukaryotes and consists of heterotrimeric complexes comprising catalytic α subunits and regulatory β and γ subunits, of which the latter carries the nucleotide-binding sites. Once activated by a metabolic stress, it phosphorylates numerous targets that alter enzyme activity and gene expression to initiate corrective responses. In lower eukaryotes, it is critically involved in the responses to starvation for a carbon source. Because of its ability to switch cellular metabolism from anabolic to catabolic mode, AMPK has become a key drug target to combat metabolic disorders associated with overnutrition such as Type 2 diabetes, and some existing anti-diabetic drugs (e.g. metformin) and many 'nutraceuticals' work by activating AMPK, usually via inhibition of mitochondrial ATP production. AMPK activators also potentially have anticancer effects, and there is already evidence that metformin provides protection against the initiation of cancer. Whether AMPK activators can be used to treat existing cancer is less clear, because many tumour cells appear to have been selected for mutations that inactivate the AMPK system. However, if we can identify the various mechanisms by which this occurs, we may be able to find ways of overcoming it.
维持产生 ATP 和消耗 ATP 的过程之间的平衡对生命至关重要。一种显而易见的方法是拥有监测 ATP 和 ADP 水平的系统,尽管由于腺苷酸激酶反应(2ADP↔ATP+AMP),AMP 实际上比 ADP 更能敏感地指示能量应激。在发现糖原磷酸化酶和磷酸果糖激酶受 AMP 和 ATP 调节之后,Daniel Atkinson 提出所有分支点处 between biosynthesis 和 degradation 的酶都将受腺嘌呤核苷酸调节。事实证明这是正确的,但 Atkinson 没有预料到的是,核苷酸的感应通常不是由代谢酶本身完成,而是由信号蛋白 AMPK(AMP 激活的蛋白激酶)完成。AMPK 基本上存在于所有真核生物中,由包含催化α亚基和调节β和γ亚基的异三聚体复合物组成,后者携带核苷酸结合位点。一旦被代谢应激激活,它就会磷酸化许多靶标,改变酶活性和基因表达,以启动纠正反应。在较低等的真核生物中,它在对碳源的饥饿反应中至关重要。由于其能够将细胞代谢从合成代谢切换到分解代谢模式,AMPK 已成为对抗与营养过剩相关的代谢紊乱的关键药物靶标,如 2 型糖尿病,一些现有的抗糖尿病药物(如二甲双胍)和许多“营养保健品”通过激活 AMPK 起作用,通常通过抑制线粒体 ATP 产生。AMPK 激活剂也可能具有抗癌作用,并且已经有证据表明二甲双胍可以预防癌症的发生。AMPK 激活剂是否可用于治疗现有癌症尚不清楚,因为许多肿瘤细胞似乎已经选择了使 AMPK 系统失活的突变。但是,如果我们能够确定发生这种情况的各种机制,我们也许能够找到克服它的方法。